Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Neurotrophic Keratitis > Topical insulin shows promising results for refractory neurotrophic keratitis
  • Neurotrophic Keratitis

Topical insulin shows promising results for refractory neurotrophic keratitis

Ophthalmology 360

Key Takeaways

  1. High efficacy: 10 IU/mL topical insulin achieved a 93.75% healing rate in refractory NK.
  2. Vision improvement: 75% of patients gained vision, averaging a 0.5 logMAR improvement.
  3. Safe & accessible: No complications, low cost, and rapid healing (~12 days on average).

Topical insulin at a concentration of 10 IU/mL showed high healing rates, improved vision, and no complications in patients with refractory neurotrophic keratitis (NK) who failed standard treatments, according to a study.

The study evaluated 16 eyes from 15 patients with stage 2 or 3 NK who were unresponsive to conventional therapies. Participants applied topical insulin drops 6 times daily, alongside prophylactic fluoroquinolone drops. Treatment continued until the persistent NK healed, with regular anterior segment imaging.

Patients began the study with poor vision, averaging 1.7 logMAR. Following treatment, 75% experienced improved visual acuity, gaining an average of 0.5 logMAR. Corneal ulcers healed in a mean of 12.3 days, and the overall healing rate reached 93.75%. No complications or side effects were observed.

According to the authors, previous studies have examined topical insulin at various concentrations, but this is the first to use 10 IU/mL. The findings indicate that topical insulin may be a highly effective, accessible, and low-cost therapy for refractory NK. The researchers note that larger studies are needed to confirm the optimal concentration and to explore its role in treating other causes of refractory corneal ulcers.

Reference

Ben Addou Idrissi S, Filali Sadouk M, et al. Role of topical insulin in the management of resistant neurotrophic corneal ulcers. J Fr Ophtalmol. 2025;49(1):104709. doi: 10.1016/j.jfo.2025.104709. Epub ahead of print. PMID: 41364970.

Share

Related Content

  • Neurotrophic Keratitis

Shelf-stable amniotic membrane improved outcomes in early-stage neurotrophic keratopathy

  • Conference Roundup

Cryopreserved amniotic membrane significantly improves ocular surface integrity in patients with severe keratoconjunctivitis sicca and neurotrophic keratopathy

  • Conference Roundup

CAM360 with a collagen shield provides rapid epithelial healing with better tolerability and safety than when used with bandage contact lenses

  • Neurotrophic Keratitis

Early detection and targeted treatment strategies are critical for optimal outcomes in neurotrophic keratitis

  • Neurotrophic Keratitis

Amniotic membrane improves severe autoimmune-related KCS and NK outcomes

  • Neurotrophic Keratitis

Systemic abnormalities commonly found in neurotrophic keratopathy patients, study finds

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon